Functional precision oncology leader kiyatec announces series c round with us$18 million closing to accelerate adoption of transformational cancer platform

Greenville s.c.--( business wire )--kiyatec inc. announced today a closing of its series c funding round totaling us$18 million from new and existing investors. new investor bruker (nasdaq: brkr) led the financing and was joined by existing investors seae ventures, venturesouth, and labcorp (nyse: lh). use of funds will focus on accelerating adoption of the company's commercially available clinical testing and preclinical pharma services, which add value across the life cycle of successful cancer drugs.
LH Ratings Summary
LH Quant Ranking